Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

48results about How to "Large population" patented technology

Method for diagnosing heart disease, predicting sudden death, and analyzing treatment response using multifractal analysis

InactiveUS6993377B2Reducing minimum sizeIncreased analytic detailMedical simulationMedical report generationTest batterySudden death
A method of analyzing electrocardiogram (EKG) data for use in the diagnosis of heart disease, prognosis of cardiac conditions, and the monitoring of heart disease therapies is disclosed. The method utilizes a wavelet-based multifractal analysis with one or more of (1) a discrete wavelet smoothing step to remove the effects of abnormal beats; (2) “Levy flight” analysis to detect the frequency of abnormal beats known to adversely affect the multifractal (MF) analysis; and (3) MF alpha analysis, a multifractal extension of monofractal short term (ST) alpha analysis. The invention further comprises an EKG test battery comprising Levy flight anomalous beat/beat cluster screening, followed by (ST) MF alpha analysis and MF Holder analysis (when validated by the Levy flight analysis). The wavelet smoothing step can also be used to classify human EKGs by observing the effect of sequential smoothing on the MF Holder coefficient. Alternative choices to the wavelet smoothing approach to removal of abnormal beat effects include probability distribution function analysis to determine the MF Holder coefficient directly, abnormal beat ridge skeleton removal to remove the offending beats based on a direct multifractal spectrum calculation, and the calculation of various types of entropy coefficients for the EKG time series.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS

Naturally occuring IgM antibodies that bind lymphocytes

Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include all immunoglobulin isotypes such as IgD, IgA and IgG. Here we describe IgM anti-lymphocyte autoantibodies (IgM-ALA) and show that these antibodies are heterogenous with some antibodies binding to chemokine receptors such as CCR5 and CXCR4 and others binding to other lymphocyte receptors including CD3, CD2, CD4 and CD81. These IgM-ALA, unlike IgG antibodies, are not cytolytic to cells at 37 C and hence function to alter lymphocyte function including cytokine production and act as “blocking antibodies to inhibit binding of chemokines and viruses including HIV-1 and Hepatitis C. IgM antibodies that bind to receptors on lymphocyte also bind to the same or similar class of receptors on other leucocytes and other cells such as cancer cells and endothelial cells. The inventor claims that naturally occurring anti-lymphocyte antibodies inhibit viral infections, cancer and several inflammatory states by binding to chemokine receptors and other cell membrane receptors that activate cells or promote viral entry and replication. Inventor also claims methods for quantitating levels of IgM-ALA with different receptor specificities to aid in preventing disease progression and also claims methods to enhance in-vivo or in-vitro production of IgM-ALA.
Owner:LOBO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products